WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis.
Abstract
235 Background: The WNT signaling pathway, dominated by APC and related regulators, is central to colorectal cancer (CRC), yet its prognostic and predictive relevance under anti-angiogenic therapy is unclear. Early-onset CRC (EOCRC), rising most rapidly among Hispanic/Latino (H/L) populations, may show context- and ancestry-specific WNT biology. We evaluated WNT alterations as candidate biomarkers for outcome stratification in bevacizumab-treated CRC. Methods: We retrospectively analyzed 2,717 CRC patients across public datasets with genomic, clinical, and treatment annotations. Eligible cases had colorectal adenocarcinoma, sequencing data, and bevacizumab exposure status. Tumors included primary and metastatic samples. Subgroups were defined by age (
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Cancer Genomics and Diagnostics
Ferroptosis and cancer prognosis
Publication details
- Journal / source
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Volume
- 44
- Issue
- 2_suppl
- Pages
- 235–235
- Publication date
- 10 January 2026
- Language
- EN